Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the total market value for post-myocardial infarction (PMI) therapeutics will reach $10 billion in 2007 and exceed $13 billion in 2012. According to the new Pharmacor study entitled Post-Myocardial Infarction, one of the factors driving the market will be the increased use of polypharmacy.

(Photo: http://www.newscom.com/cgi-bin/prnh/20030626/DECLOGO )

"Improved physician and patient education will encourage greater use of polypharmacy in PMI; antiplatelet agents, angiotensin-converting enzyme (ACE) inhibitors, beta blockers, and lipid-lowering therapies will all benefit from this increased awareness," said Jeremy Quirk, Ph.D., M.B.A., analyst at Decision Resources. "Within these classes, patient share will grow most strongly for atorvastatin following the release of positive mortality data in PMI and for clopidogrel following patent expiration in the first half of our study period."

Disease Facts--Post-Myocardial Infarction

According to the American Heart Association, 25% of men and 38% of women will die within one year after having an acute myocardial infarction. Compared with the general population, they have four to six times the risk of sudden death, even though long-term survival after acute myocardial infarction has improved dramatically in recent years. The high level of mortality in the PMI population is in part caused by inadequate treatment of these patients, and this treatment shortcoming will be exacerbated by an increase in the PMI population, driven by improving survival rates after acute myocardial infarction; an aging population that is more at risk for acute myocardial infarction; a new definition of acute myocardial infarction based on troponin measurements; and improved diagnosis rates.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Post-Myocardial Infarction is a Cardium study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030626/DECLOGO
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com

Level of Reimbursement is the Most Influential Factor in Restricting Physician use of Serotonin Receptor Antagonists in the Treatment of Side Effects of Chemotherapy

View Now